26 results about "Hsv infection" patented technology

The present disclosure provides, in part, azetidine compounds, and pharmaceutical compositions thereof, and methods of the treatment and prophylaxis of HSV infections.

The present disclosure relates to compositions and methods for treating or preventing neonatal herpes simplex virus (HSV) infection and / or the neurological and / or non-neurological sequelae thereof.

The present invention relates to the treatment of herpes simplex virus (HSV) infection using anti-HSV antibodies. Specifically, the anti-HSV antibody specifically binds to glycoprotein D (gD) of herpes simplex virus-1 (HSV-1) and herpes simplex virus-2 (HSV-2). The treatment of the invention is effective against drug resistant and / or recurrent HSV infection.

The present disclosure provides, in part, tricyclic compounds, and pharmaceutical compositions thereof, and methods of the treatment and prophylaxis of HSV infections.

This invention belongs to the field of natural and chemical medicine technology, and discloses two types of *Symplocos edulis* (a type of plant) from the genus *Symplocos*. Bag Philippians The resorcinol compounds were isolated from [the organism]. The structures of the resorcinol compounds are shown in formula (I) or formula (II). The resorcinol compounds of this invention exhibit significant inhibitory effects on respiratory syncytial virus (RSV) and herpes simplex virus (HSV) even at low concentrations, and show low cytotoxicity and high selectivity, demonstrating promising applications in antiviral drugs and medications for treating diseases caused by RSV and HSV infections.

This invention relates to an HSV-2 nanoparticle vaccine, its preparation method, and its application. The nanoparticles comprise HSV-2 PreF gB mutant protein and ferritin. After assembly, multiple PreF gB mutant proteins are concentrated and displayed on the surface, forming ferritin-PreF gB nanoparticles. The mutation of PreF gB enhances the stability and effective immunogenicity of the gB protein, and its display on the nanoparticle surface further enhances immunogenicity, effectively stimulating the body's cellular immune mechanism, thus becoming an effective vaccine for preventing HSV infection.

The invention provides an application of an IL-37b gene in preparation of a medicine for preventing and treating diseases caused by HSV infection. In animal model experiments, overexpression of the IL-37b delta1-45 gene can significantly prevent HSK recurrence, relieve corneal functions of a recurrent mouse model, relieve corneal tissue inflammation infiltration, relieve corneal stromal layer fibrosis level and significantly reduce viral load in mouse tears, which prompts that IL-37b delta1-45 is expected to become a new method for preventing HSK recurrence. Wide application prospects are realized.

The present disclosure provides, in part, tricyclic compounds, and pharmaceutical compositions thereof, and methods of the treatment and prophylaxis of HSV infections.

The present disclosure provides a combination comprising ribonucleotide sequences that encode herpes simplex virus (HSV) glycoproteins, including those involved in virus entry and immune evasion and related methods of treating, suppressing, inhibiting, or preventing an HSV infection. The present disclosure further provides a related formulation comprising ribonucleotide sequences that encode HSV glycoproteins, wherein one or more of the ribonucleotides are fully or partially encapsulated within a lipid nanoparticle, wherein the lipid nanoparticle comprises (a) a polymer-conjugated lipid; (b) a cationic lipid; and (c) one or more neutral lipids. Finally, the present disclosure provides methods of inducing an HSV glycoprotein-specific B-cell response in a subject comprising administering to the subject a composition comprising the HSV glycoprotein.

The invention relates to an HSV-2 type nanoparticle vaccine as well as a preparation method and application thereof, the nanoparticle comprises HSV-2 PreF gB mutant protein and ferritin, and after the HSV-2 PreF gB mutant protein and ferritin are assembled, a plurality of ferritin-PreF gB nanoparticles of which the PreF gB mutant protein is intensively displayed on the surface are obtained. After PreF gB is mutated, the stability and the effective immunogenicity of gB protein are enhanced, the immunogenicity is further enhanced through display on the surfaces of the nanoparticles, the cellular immune mechanism of an organism can be effectively stimulated, and the preF gB becomes an effective vaccine for preventing HSV infection.

The present disclosure provides, in part, tricyclic compounds, and pharmaceutical compositions thereof, and methods of the treatment and prophylaxis of HSV infections.

The present disclosure provides, in part, tricyclic compounds, and pharmaceutical compositions thereof, and methods of the treatment and prophylaxis of HSV infections.

This application discloses the application of the IL-37b gene in the preparation of drugs for the prevention and treatment of diseases caused by HSV infection. In animal model experiments, overexpression of the IL-37bΔ1-45 gene significantly prevented HSK relapse and alleviated corneal function in relapsed mouse models, reduced corneal tissue inflammation and infiltration, reduced corneal stromal fibrosis, and significantly decreased viral load in mouse tears, suggesting that IL-37bΔ1-45 may be a promising new method for preventing HSK relapse and has broad application prospects.

The present disclosure provides, in part, azetidine compounds, and pharmaceutical compositions thereof, and methods of the treatment and prophylaxis of HSV infections.

Disclosed herein are compositions comprising (a) a nucleoside modified polyribonucleotide encoding a herpes simplex virus-2 (HSV-2) glycoprotein E (gE) antigen or an immunogenic fragment thereof, (b) a nucleoside modified polyribonucleotide encoding a HSV-2 glycoprotein I (gI) antigen or an immunogenic fragment thereof, or (c) a combination thereof. Further disclosed are methods for treating HSV infection using the compositions.

The invention relates to an HSV-1 type nanoparticle vaccine and a preparation method and application thereof.The nanoparticle comprises HSV-1 PreF gB mutant protein and ferritin, and after assembling, a plurality of ferritin-PreF gB nanoparticles with the PreF gB mutant protein displayed on the surface in a centralized mode are obtained. After PreF gB is mutated, the stability and the effective immunogenicity of gB protein are enhanced, the immunogenicity is further enhanced through display on the surfaces of the nanoparticles, the cellular immune mechanism of an organism can be effectively stimulated, and the preF gB becomes an effective vaccine for preventing HSV infection.

Disclosed herein are compositions comprising (a) a nucleoside-modified polyribonucleotide encoding a Herpes Simplex Virus-2 (HSV-2) glycoprotein E (gE) antigen or immunogenic fragment thereof, (b) a nucleoside-modified polyribonucleotide encoding an HSV-2 glycoprotein I (gI) antigen or immunogenic fragment thereof, or (c) a combination thereof. Further disclosed are methods for using said compositions for treating an HSV infection.

Described is a vaccine for use in actively immunising a subject against an infectious disease or a malignant disease, said vaccine comprising: (a) an antibody against an antigen correlated with said infectious disease or malignant disease; or (b) an Fc-containing fusion protein comprising an Fc part of an antibody fused to an antigen correlated with said infectious disease or malignant disease, wherein said Fc part is capable of binding a receptor present on or in an antigen presenting cell (APC) selected from the group consisting of Type I: activatory FcγRI, FcγRIIa, FcγRIIc, FcγRIIIa, FcγRIIIb, and inhibitory FcγRIIb; and Type II: neonatal FcR (FcRn) and cytosolic TRIM21. Moreover, described is a vaccine for use in actively immunising a subject against an HSV-associated disease; and (a) wherein said antibody is an anti-HSV antibody and said subject suffers from an acute HSV-associated disease, preferably an acute HSV infection; or (b) wherein in said Fc-containing fusion protein comprising an Fc part of an antibody fused to an antigen, the antigen correlates with an HSV-associated disease.

The present disclosure provides, in part, cyclic urea thiazolyl compounds, and pharmaceutical compositions thereof, and methods for treating and preventing HSV infection. In one embodiment, the disclosure provides a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein the variables are as described herein. In another aspect, the disclosure provides a pharmaceutical composition comprising a compound of Formula I or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient. In another aspect, the disclosure provides a method of treating an HSV infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula I, or a pharmaceutically acceptable salt thereof.

This invention provides methods of treating, suppressing, inhibiting, reducing an incidence, reducing the pathogenesis of, ameliorating the symptoms of, or ameliorating the secondary symptoms of a primary or recurring Herpes Simplex Virus (HSV) infection, or prolonging the latency to a relapse of an HSV infection, and disorders and symptoms associated with same in a subject comprising the step of contacting the subject with a composition comprising a quindoline (or similar) structure having significant anti-HSV activity.

The invention provides application of venenum bufonis and bufalin in preparation of a herpes simplex virus inhibitor, herpes simplex virus is HSV-1 or acyclovir drug-resistant virus strain HSV-1 / 153, a disease caused by HSV infection is herpes keratitis or herpes progenitalis disease infection, and the invention further discloses a pharmaceutical composition. Venenum bufonis and bufalin are used as active components or main active components, and a pharmaceutically acceptable carrier is supplemented.

The present invention pertains to the fields of antibody technology, medicine, pharmacology, infection biology, and medical diagnostics. More specifically, the present disclosure provides a VHH antibody that neutralizes herpes simplex viruses HSV-1 and HSV-2 by blocking the pre-fusion state of the gB fusion protein, as well as methods for using this VHH against HSV infections.

This invention relates to an HSV-1 nanoparticle vaccine, its preparation method, and its application. The nanoparticles comprise HSV-1 PreF gB mutant protein and ferritin. After assembly, multiple PreF gB mutant proteins are concentrated and displayed on the surface, forming ferritin-PreF gB nanoparticles. The mutation of PreF gB enhances the stability and effective immunogenicity of the gB protein, and its display on the nanoparticle surface further enhances immunogenicity, effectively stimulating the body's cellular immune mechanism, thus becoming an effective vaccine for preventing HSV infection.

The present disclosure provides, in part, azetidine compounds, and pharmaceutical compositions thereof, and methods of the treatment and prophylaxis of HSV infections.

Described is a vaccine for use in active immunization of a subject against an infectious or malignant disease, the vaccine comprising: (a) an antibody against an antigen associated with the infectious or malignant disease; or (b) an Fc-containing fusion protein comprising an Fc portion of an antibody fused to an antigen associated with the infectious disease or malignant disease wherein the Fc portion is capable of binding to a receptor present on or in an antigen presenting cell (APC) selected from the group consisting of Type I: activating Fc [gamma] RI, Fc [gamma] RIIa, Fc [gamma] RIIc, Fc [gamma] RIIIa, Fc [gamma] RIIIb, and inhibitory Fc [gamma] RIIIb; and Type II: neonatal FcR (FcRn) and cytoplasmic TRIM21. In addition, a vaccine for use in active immunization of a subject against an HSV-related disease is described; and (a) wherein the antibody is an anti-HSV antibody and the subject is suffering from an acute HSV-related disease, preferably an acute HSV infection; or (b) wherein in the Fc-containing fusion protein comprising an Fc portion of an antibody fused to an antigen, the antigen is associated with a HSV-related disease.